Exozymes Inc.
EXOZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002010788
In the last 90 days, Exozymes Inc. insiders filed 1 open-market purchase and 0 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.05M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Exozymes Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 7
- +1 vs. Q3 2025
- Shares held
- 62.6K
- +2.68K (+4.5%) vs. Q3 2025
- Total value
- $682.4K
- −$198.0K (−22.5%) vs. Q3 2025
- New holders
- 1
- 3 more added
- Sold out
- 0
- 2 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EXOZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $1.05M |
| Q1 2026 | 7 | $471.8K |
| Q4 2025 | 7 | $682.4K |
| Q3 2025 | 6 | $880.4K |
| Q2 2025 | 9 | $727.4K |
| Q1 2025 | 6 | $802.2K |
| Q4 2024 | 7 | $1.62M |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Exozymes Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 31,516 | $343.5K | 0.00% | +5,535+21.3% | Added |
| Geode Capital Management, LLC | 23,562 | $256.8K | 0.00% | +499+2.2% | Added |
| BlackRock, Inc. | 6,251 | $68.1K | 0.00% | +1,266+25.4% | Added |
| Morgan Stanley | 1,250 | $13.6K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 17 | $185 | 0.00% | −6−26.1% | Reduced |
| UBS Group AG | 3 | $33 | 0.00% | −4,618−99.9% | Reduced |
| Tower Research Capital LLC (TRC) | 2 | $22 | 0.00% | +2 | New |